SAGE Therapeutics Inc Conference Call to Discuss Collaboration with Biogen Inc Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Jeff, nice to hear you back on the call. On zuranolone, can you at least qualitatively talk about what data specifically on safety or efficacy that Biogen may have seen that outsiders have not? And how are the soon-to-be-partners thinking about the competitive profile of zuranolone versus PRAX-114, for example?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : And Jeff, good to hear you. As you and Biogen rethink the development path for zuranolone in depression specifically, what could potentially change in any sort of meaningful way? So will you look at additional types of studies in depression or just accelerate the REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 30, 2020 / 1:00PM, SAGE.OQ - SAGE Therapeutics Inc Conference Call to Discuss Collaboration with Biogen Inc existing studies? And then should we expect a potential filing for the initial indication? Would that be pushed out or then accelerated? What's a reasonable time frame for that?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : So just to confirm, that would lead to the initial depression indication as well.